Filing Details
- Accession Number:
- 0001562180-22-002161
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-03-02 21:10:24
- Reporting Period:
- 2022-02-28
- Accepted Time:
- 2022-03-02 21:10:24
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1517022 | Akebia Therapeutics Inc. | AKBA | Pharmaceutical Preparations (2834) | 208756903 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1602396 | R. Nicole Hadas | C/O Akebia Therapeutics, Inc. 245 First Street Cambridge MA 02142 | Svp, Chief Legal Officer | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2022-02-28 | 6,555 | $2.15 | 265,748 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2022-02-28 | 50,000 | $0.00 | 315,748 | No | 4 | A | Direct | |
Common Stock | Disposition | 2022-03-01 | 6,873 | $2.17 | 308,875 | No | 4 | S | Direct | |
Common Stock | Disposition | 2022-03-01 | 6,556 | $2.17 | 302,319 | No | 4 | S | Direct | |
Common Stock | Disposition | 2022-03-01 | 1,078 | $2.17 | 304,241 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | A | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Employee Stock Option (Right to buy) | Acquisiton | 2022-02-28 | 200,000 | $0.00 | 200,000 | $2.16 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
200,000 | 2032-02-28 | No | 4 | A | Direct |
Footnotes
- This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021.
- The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One-third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.
- This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2019.
- This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2020.
- This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021.
- Includes 1,500 shares of the Issuers common stock purchased on June 30, 2021 and 1,500 shares of the Issuers common stock purchased on December 31, 2021, each under the Issuers 2014 Amended and Restated Employee Stock Purchase Plan.
- The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.